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Abstract 
 
Context: MRI-targeted prostate biopsy (MRI-TB) may be an alternative to systematic biopsy 
for diagnosing prostate cancer.  
 
Objective: The primary aims of this systematic review and meta-analysis were to compare 
the detection rates of clinically significant and clinically insignificant cancer by MRI-TB to 
systematic biopsy in men undergoing prostate biopsy to identify prostate cancer. 
 
Evidence acquisition: A literature search was conducted using the PubMed, Embase, Web of 
Science, Cochrane library and Clinicaltrials.gov databases. We included prospective and 
retrospective paired studies where the index test was MRI-TB and the comparator test was 
systematic biopsy. We also included randomized controlled trials (RCTs) if one arm included 
MRI-TB and another arm included systematic biopsy. The risk of bias was assessed using a 
modified Quality Assessment of Diagnostic Accuracy Studies-2 checklist. In addition, the 
Cochrane risk of bias 2.0 tool was used for RCTs. 
 
Evidence Synthesis: We included 68 studies with a paired design and 8 RCTs, comprising a 
total of 14709 men who received either both MRI-TB and systematic biopsy or were 
randomized to receive one of the tests. 
 
MRI-TB detected more men with clinically significant cancer than systematic biopsy 
(Detection ratio (DR) 1.16 [95% CI 1.09-1.24], p < 0.0001) and fewer men with clinically 
insignificant cancer than systematic biopsy (DR 0.66 [95% CI 0.57-0.76], p < 0.0001). The 
proportion of cores positive for cancer was greater for MRI-TB than systematic biopsy, 
relative risk 3.17 [95% CI 2.82-3.56], p<0.0001. 
 
Conclusions: MRI-TB is an attractive alternative diagnostic strategy to systematic biopsy. 
 
Patient summary: 
We evaluated the published literature, comparing two methods of diagnosing prostate 
cancer. We found that biopsies targeted to suspicious areas on an MRI (MRI-Targeted 
biopsy) were better at detecting prostate cancer that needs to be treated and at avoiding 
the diagnosis of disease that doesn’t need treatment than the traditional systematic biopsy. 
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1. Introduction 
 
Multiparametric magnetic resonance imaging (mpMRI) has an increasingly important role in 
the diagnosis of prostate cancer [1-3]. The MRI information can be used to guide prostate 
biopsy cores to suspicious areas in the prostate [4]. The traditional diagnostic pathway of 
systematic biopsy with 10-12 core transrectal ultrasound-guided prostate (TRUS) biopsy, in 
men with raised prostate specific antigen (PSA), has been challenged by evidence from 
systematic reviews and randomized controlled trials (RCTs). There is support for an 
alternative pathway where men with suspicious MRIs only undergo biopsy of MRI-suspicious 
areas, MRI-targeted biopsy (MRI-TB) [1, 5-8]. Potential advantages are maintaining or 
improving the rates of detection of clinically significant disease, using fewer biopsies in 
fewer men. In addition, detection of clinically insignificant disease, and associated 
overtreatment, are reduced [9-12]. This pathway has the potential to be cost-effective in a 
number of different healthcare settings [13-15].  
 
The primary aim of this systematic review and meta-analysis was to compare the detection 
rates of clinically significant and clinically insignificant cancer by MRI-targeted biopsy versus 
systematic biopsy in men with a suspicion of clinically significant prostate cancer with raised 
PSA or abnormal digital rectal examination. The main focus of the review was to assess 
whether MRI-TB (with biopsies only to suspicious areas on MRI) could replace systematic 
biopsy as a diagnostic test for prostate cancer. Previous systematic reviews in this field 
highlighted limitations in the quality of reporting in the included studies [7]. The Standards 
of Reporting for MRI-targeted Biopsy Studies (START) of the Prostate Consortium aimed to 
address this and here, we review the published literature since these standards were 
released [4]. “Systematic biopsy” is a term that encompasses several different types of 
biopsy approaches. Though the most commonly used type of systematic biopsy is TRUS 
biopsy, transperineal template biopsy (TPM) is becoming an increasingly used systematic 
biopsy technique. A comparison of MRI-TB to transperineal template biopsy (TPM) has not 
been addressed in previous reviews and thus was also included in this review.  
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2. Evidence Acquisition 
 
This systematic review was reported according to the Preferred Reporting Items for 
Systematic reviews and Meta-Analyses (PRISMA) guidelines, and relevant aspects of the 
diagnostic test accuracy extension (PRISMA-DTA) [16]. The review was registered in the 
International prospective register of systematic reviews (PROSPERO), ID CRD42015017543. 
 
2.1 Search strategy 
 
A literature search was conducted with the assistance of an information specialist using the 
PubMed, Embase, Web of Science, Cochrane library and Clinicaltrials.gov databases (see 
Supplementary Appendix 1). We searched from inception of the databases up to the 28th 
July 2017. To capture the latest evidence, authors of studies identified in the 
Clinicaltrials.gov database search as ongoing were contacted, and if the full paper was 
available prior to completing data extraction on 8th July 2018, they were eligible for 
inclusion. 
 
2.2 Inclusion and exclusion criteria 
 
We included prospective and retrospective paired studies, where the index test was MRI-TB 
and the comparator test was systematic biopsy. We also included RCTs if one arm included 
MRI-TB and another arm included systematic biopsy. Studies needed to report the number 
of men with at least one of the target conditions (significant prostate cancer, insignificant 
prostate cancer or any prostate cancer based on histological definitions) in those with raised 
PSA or abnormal digital rectal examination. MRI-TB was defined as a biopsy in which mpMRI 
information was used to influence the conduct of the prostate biopsy. For a study to be 
eligible, it was necessary to be able to derive the cancer detection specifically from the 
biopsies taken from MRI suspicious areas. Systematic biopsy was defined as TRUS or TPM 
biopsy. Since there is no accepted definition of clinically significant or clinically insignificant 
cancer, definitions used in individual studies were permitted. If the definition was not 
specified but cancer detection was presented by Gleason grade, then cancer with Gleason 
grade 3+4 or greater was considered clinically significant and cancer with Gleason grade 3+3 
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was considered clinically insignificant [1]. Studies were not excluded on basis of language. 
When multiple publications including overlapping cohorts were reported, only the most 
recent or relevant cohort to the review objectives was included.  
 
 
2.3 Study selection and data collection 
 
Screening of studies was carried out using Covidence© software. Prior to screening, all 
reviewers underwent a pilot screening process to ensure consistency in reviewing. Each title 
and abstract was screened independently by two reviewers from a team of 10 (VK, AS, JN, 
FG, MV, YS, KC, DS, YP, DT). Reviewers were selected from the BURST Research collaborative 
[17] on the basis of expertise in MRI-targeted prostate biopsy and/or in the conduct of 
systematic reviews. Full text articles were reviewed for inclusion independently by two of 
the reviewers. Data from each study were extracted independently by two of the reviewers. 
Data were collected in line with the START criteria [4] and a list of items collected is given in 
Supplementary appendix 2. Where appropriate, authors were contacted to provide missing 
data and blank tables were sent to them for completion. After each stage of the screening, 
inclusion and extraction process, discrepancies between reviewers were resolved via 
consensus, adjudicated by a third reviewer (one of VK, JN).  
 
2.4 Quality assessment of included studies 
 
The risk of bias and applicability concern in individual studies was assessed independently, 
by two reviewers using a modified Quality Assessment of Diagnostic Accuracy Studies-2 
(QUADAS-2) checklist (Supplementary Appendix 3). RCTs were also assessed using the 
Cochrane risk of bias 2.0 tool for RCTs. Discrepancies between reviewers were resolved via 
consensus, adjudicated by a third reviewer (one of VK, JN).  
 
2.5 Data synthesis 
 
Since there is no ideal reference standard in prostate cancer diagnosis, we compared the 
detection rates of MRI-TB and systematic biopsy for each target condition. Our primary 
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analysis was the comparison of clinically significant cancer detection rates. Detection rates 
were calculated as the number of men with the target condition divided by the number of 
men who had the test. A detection ratio (DR) was calculated as the MRI-TB detection rate 
divided by the systematic biopsy detection rate. Thus, a DR > 1 indicates that MRI-TB 
detected more of the target condition than systematic biopsy. Studies with a paired design 
and RCTs were analysed separately. For meta-analyses of the DRs from paired studies, if 
both MRI-TB and systematic biopsy were performed on men in one arm of an RCT and 
paired data were available, we included the data as a paired study. The within-study 
variance was calculated for each paired study, taking into account the correlation between 
the detection rates of MRI-TB and systematic biopsy since both tests were performed on 
each patient. We synthesised detection ratios using the DerSimonian and Laird random 
effects approach [18]. Further details on data synthesis techniques are given in 
Supplementary Appendix 4. 
 
Heterogeneity between studies was measured using the I2 statistic and the between study 
variance (τ2) from the random effects analyses. We performed the following planned 
sensitivity analyses:  
i. Significant cancer detection rates defined as any Gleason 3+4 prostate cancer or 
greater.  
ii. Significant cancer detection rates defined as any Gleason 4+3 prostate cancer or 
greater.  
iii. Insignificant cancer detection defined as Gleason 3+3 prostate cancer. 
 
In addition, we performed a post hoc sensitivity analysis, which limited analysis to studies 
with at least 100 men and 50 cancer cases diagnosed. For assessment of publication bias 
and small study effects, log-transformed values of the detection ratios were plotted against 
their standard error in a contour enhanced funnel plot.  
 
To assess differences between subgroups, the following covariates were specified a priori:  
i. Systematic biopsy type (TRUS-biopsy or TPM) 
ii. Prior biopsy status (biopsy naïve, prior prostate biopsy negative for cancer and prior 
biopsy positive for cancer) 
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iii. Type of MRI-TB (cognitive registration/visual registration, software-assisted 
registration/fusion software, in-bore biopsy) 
 
We performed univariable meta-regression analyses using random-effects models to 
statistically assess differences in detection ratios between subgroups.  
  
We assessed three additional outcomes: 
i. Proportion of cores positive for prostate cancer by MRI-TB compared to systematic 
biopsy  
ii. Proportion of men having MRI-TB and systematic biopsy, who had cancer upgraded 
or downgraded on subsequent radical prostatectomy 
iii. Proportion of clinically significant cancer missed by MRI-TB but detected by the 
addition of systematic biopsy 
 
All statistical analyses were performed in Stata version 15.  
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3. Evidence Synthesis 
 
3.1 Summary of studies  
 
Figure 1 shows the flow of studies through the screening process. Of 7398 studies included 
in the screening phase, 76 studies were considered eligible for inclusion, of which 68 were 
studies with a paired design and 8 were RCTs, including a total of 14709 men who received 
either both MRI-TB and systematic biopsy or were randomized to receive only one of the 
tests. Study characteristics for paired studies are given in Table 1a [5, 19-89] and for the 
RCTs in Table 1b [1, 5, 6, 20, 21, 79, 90, 91].  
 
3.2 Risk of bias within studies  
 
The risk of bias and applicability concern is given in supplementary appendix 5a and 6. The 
overall methodological quality of the studies was moderate, with 14 having low risk of bias 
and applicability concern across all domains assessed. Supplementary appendix 5b 
summarises the additional items assessed for each RCT using the Cochrane risk of bias 2.0 
tool. Overall methodological quality of the RCTs was good with 5 of the 8 studies rated as 
having low risk of bias across all domains and none of the studies having a domain at high 
risk of bias. 
 
 
3.3 Studies with paired data 
 
3.3.1 Clinically significant cancer detection 
 
56 study cohorts including 4652 patients were included in the analysis. This includes data 
from the MRI arm of four RCTs where both MRI-TB and systematic biopsy were carried out 
in the same patient [5, 20, 21, 79]. The definition of clinically significant cancer in each study 
is given in Table 1a. MRI-TB detected more men with clinically significant cancer than 
systematic biopsy (DR 1.16 [95% CI 1.09-1.24], p < 0.0001) (Figure 2). This effect was also 
evident in sensitivity analyses where the definition of clinically significant cancer was 
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Gleason 3+4 or greater (DR 1.09 (95% CI 1.02-1.18), p = 0.018) (Supplementary Appendix 7) 
or where the stricter definition of Gleason grade 4+3 or greater was used (DR 1.38 (95% CI 
1.14-1.68), p = 0.001) (Supplementary Appendix 8). Publication bias was assessed by visual 
inspection of a contour enhanced funnel plot (supplementary appendix 9). There was 
indication of funnel plot asymmetry though many studies differing in precision were in the 
regions of statistical non-significance (5% < p <10% and p > 10%). Therefore, publication bias 
or small study effects may be absent. A subsequent sensitivity analysis that included only 
studies with greater than 100 patients and 50 cancer cases showed results consistent with 
the primary analysis (DR 1.19 (95% CI 1.09-1.30), p < 0.0001) (Supplementary appendix 10).   
 
There was some evidence in the meta-regression analysis to suggest that the superiority of 
MRI-TB relative to systematic biopsy may depend on the type of comparator, with MRI-TB 
performing better when the comparator was TRUS biopsy (DR 1.22 [95% CI 1.13-1.32]) than 
when the comparator was TPM biopsy (DR 0.99 [95% CI 0.91-1.07], difference between 
subgroups, p = 0.083). There was no evidence of differences by prior biopsy status (biopsy 
naïve DR 1.18 [95% CI 1.06-1.31]), prior biopsy negative DR 1.22 [95% CI 1.05-1.42], prior 
biopsy positive DR 1.09 [95% CI 0.92-1.30], difference between subgroups, p = 0.71) or by 
type of MRI-TB registration method (fusion biopsy DR 1.22 [95% CI 1.12-1.33], cognitive 
registration DR 1.11 [95% CI 0.94-1.31], difference between subgroups, p = 0.36). A 
summary of these results is given in Table 2. 
 
3.3.2 Clinically insignificant cancer detection 
 
46 study cohorts including 2124 patients were included in the analysis. MRI-TB detected 
fewer men with clinically insignificant cancer than systematic biopsy (DR 0.66 [95% CI 0.57-
0.76], p < 0.0001) (Figure 3). This effect was also evident in the sensitivity analysis that 
defined clinically insignificant cancer as Gleason grade 3+3 (DR 0.74 (95% CI 0.65-0.84), p < 
0.0001) (Supplementary Appendix 11).  
 
There was no evidence from meta-regression analysis that this effect differed by systematic 
biopsy type (MRI-TB vs TRUS biopsy, DR 0.64 [95% CI 0.54-0.76], MRI-TB vs TPM biopsy, DR 
0.74 [95% CI 0.60-91]), difference between subgroups, p = 0.61), by prior biopsy status 
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(biopsy naïve DR 0.71 [95% CI 0.51-0.96]), prior biopsy negative DR 0.48 [95% CI 035-0.66], 
prior biopsy positive DR 0.51 [95% CI 0.40-0.66], difference between subgroups, p=0.12) or 
by registration choice (cognitive registration (DR 0.81 [95% CI 0.56-1.17]) or fusion biopsy 
(DR 0.64 [95% CI 0.56-0.73]), difference between subgroups, p = 0.14). A summary of these 
results is given in Table 3. 
 
3.3.3 Any cancer detection 
 
61 study cohorts including 6742 patients were included in the analysis. There was no 
difference in any cancer detection by MRI-TB compared to systematic biopsy (DR 1.02 [95% 
CI 0.96-1.08], p = 0.49), Supplementary appendix 12.  
 
3.4 Randomized controlled trials 
 
Eight RCTs of 2635 patients (Table 1b) presented results for clinically significant cancer and 
insignificant cancer detection. The two RCTs which most directly addressed the review 
objectives used MRI-TB alone as the index test when the MRI was suspicious and compared 
this to a comparator arm of TRUS biopsy alone, showing a clear benefit for the MRI arm 
over the TRUS-biopsy arm (DR 1.46 [95% CI 1.12-1.90] and DR 2.43 [95% CI 1.53-3.84], 
Figure 4a) [ [1, 6].  However, due to heterogeneity amongst the RCTs in how MRI 
information was used to influence a decision for biopsy, how that biopsy was conducted and 
in the choice of index and comparator tests, we did not conduct meta-analysis of all RCTs. 
We meta-analysed a subset of 5 RCTs which compared MRI-TB plus TRUS biopsy to TRUS 
biopsy alone. MRI-TB plus TRUS biopsy detected more men with clinically significant cancer 
than TRUS biopsy alone (DR 1.21 [95% CI 0.94-1.57], though this difference was not 
statistically significant (p = 0.14).  
 
For clinically insignificant cancer detection (Figure 4b), the two RCTs of MRI-TB alone in MRI-
suspicious men versus TRUS biopsy, showed lower detection rates for MRI-TB compared to 
TRUS biopsy [1, 6]. However, after meta-analysis of the 4 RCTs of MRI-TB plus TRUS biopsy 
versus TRUS biopsy alone, this benefit was no longer seen (DR 1.11 [95% CI 0.49-2.51], p = 
0.80).     
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In 4 of the 8 RCTs, men with a negative MRI were biopsied and the proportion of clinically 
significant cancer were 0/23 (0%) [21], 0/130 (0%) [5], 1/26 (4%) [6] and 3/13 (23%) [79].   
 
3.6 Proportion of cores positive for cancer 
 
The proportion of cores positive for prostate cancer was reported in 18 studies comprising 
2045 men. The proportion of cores positive for cancer was 2464 out of 7866 (31%) for MRI-
TB and 3943 out of 35873 (11%) for systematic biopsy. The proportion of cores positive for 
cancer was greater for MRI-TB than systematic biopsy, RR 3.17 [95% CI 2.82-3.56], p 
<0.0001 (Supplementary Appendix 13).  
 
3.7 Proportion of men with cancer upgraded or downgraded on radical prostatectomy 
 
There was one study which reported both the proportion of men with cancer upgraded or 
downgraded by radical prostatectomy for MRI-TB and systematic biopsy [1]. In this study 
4/27 (15%) men undergoing TRUS biopsy were upgraded compared to 5/30 (17%) men 
undergoing MRI-TB, who were upgraded. For downgrading, 4/27 (15%) men were 
downgraded from TRUS biopsy to radical prostatectomy and 6/30 (20%) were downgraded 
from MRI-TB to radical prostatectomy.  
 
3.8 Proportion of men with clinically significant cancer missed by MRI-TB but detected by 
the addition of systematic biopsy 
 
56 study cohorts including 4652 patients were included in the analysis. The definition of 
clinically significant cancer in each study is given in Table 1a. The proportion of men with 
clinically significant cancer missed by MRI-TB but detected by the addition of systematic 
biopsy was 13% [95% CI 10-16%], p < 0.0001 (Supplementary Appendix 14).  
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Discussion 
 
The principal findings of this systematic review are that in men with suspected clinically 
significant prostate cancer with raised PSA or an abnormal digital rectal examination, MRI-
TB detects more clinically significant cancer and less clinically insignificant cancer than 
systematic biopsy, requiring fewer cores than systematic biopsy to achieve this. These 
findings were consistent across a range of different thresholds for defining significant and 
insignificant cancer. The clinical implications are that using an MRI-targeted biopsy strategy 
could identify those men who will benefit from treatment, and allow men at lowest clinical 
risk to avoid unnecessary biopsy and potentially, overtreatment. 
 
There was no evidence that these findings varied by whether men were biopsy naïve or had 
had a prior biopsy. Previously, international guidelines have recommended the use of MRI in 
men with a prior negative biopsy [92, 93], but the present findings support its role in all men 
who require further diagnostic testing. There was also no evidence that these findings 
varied whether MRI-TB was carried out with cognitive or image-fusion registration 
techniques. This is also consistent with findings from recent trials and systematic reviews 
[94-96].  
 
Previous systematic reviews have not compared the performance of MRI-TB with systematic 
TPM biopsy. In this review, the comparative performance of MRI-TB appeared to be 
influenced by the choice of systematic biopsy, with MRI-TB performing better when the 
comparator was TRUS biopsy than when the comparator was TPM biopsy. This is consistent 
with what one might expect from the more intensive sampling approach of a TPM, which 
when compared directly to TRUS biopsy has been shown to identify more clinically 
significant cancer [2]. MRI-TB appeared to be comparable to the intensive sampling regime 
of TPM, as demonstrated in previous studies [48], but is far more efficient, requiring fewer 
cores. Fewer biopsy cores may avoid the significant side effects seen with TPM [97] whilst 
allowing the possibility of a local anaesthetic office-based approach [98].  
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In the one study reporting upgrading and downgrading by radical prostatectomy, MRI-TB 
and systematic biopsy appeared to have similar results, though further data in this area is 
needed to make any firm conclusions. 
 
In the paired studies analysed, when performing MRI-TB and TRUS biopsy in the same 
biopsy session, it is possible that conduct of one test could have influenced the performance 
of the other. For example, knowledge of where the MRI-targets were could have improved 
the performance of the systematic biopsy. This review did identify RCTs which allowed us to 
explore the performance of MRI-TB independently of TRUS biopsy and vice versa; MRI-TB 
detected more clinically significant cancer than TRUS biopsy in the RCTs most relevant to 
the review’s objectives [1, 6]. It was also evident from the 4 pooled RCTs, that combining 
MRI-TB with TRUS biopsy diminished the benefit of MRI-TB in reducing clinically insignificant 
cancer detection [21, 79, 90, 91].  
 
The RCTs also presented an opportunity to explore cancer detection rates in men with non-
suspicious MRIs. In 3 of the 4 RCTs where clinically significant cancer was reported, this was 
low (0-4%) [5, 6, 21] but was higher in the remaining study (3/13, 23%), albeit in a small 
sample [79]. Clearly if a strategy of avoiding biopsy in men with negative MRI and low 
clinical risk of prostate cancer is to be adopted, then further follow up in these men is 
important, though level 1 evidence would support the concept that a negative MRI has a 
higher negative predictive value than TRUS biopsy [2] and that a negative MRI is more 
reassuring to patients and clinicians than a negative TRUS biopsy [1]. Emerging data from 
key recently published studies, including the MRI-FIRST study, 4M Study and Panebianco et 
al also support the concept of incorporating MRI into the diagnostic pathway [3, 99, 100]. 
 
There are a number of limitations in this review. First, it is important to appreciate that 
there is a bias introduced by analysing studies with a paired design as the conclusions of 
such data are limited to men with MRIs with suspicious findings who underwent both MRI-
TB and systematic biopsy. An RCT design would mitigate some of this bias and although this 
systematic review included several RCTs, the majority did not perfectly address the primary 
question of this review in terms of the index test and comparator.  
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Second, there was substantial between-study variability in most of the meta-analyses, as 
indicated by the magnitude of the I2 statistic. Although there was variation in the direction 
of effect, confidence intervals for studies generally overlapped. Thus, the I2 values may be 
misleading as I2 is known to increase with the precision of the studies [101], and many 
studies in the main analysis of clinically significant cancer had high precision, as is evident on 
the funnel plot. Furthermore, due to the large number of included studies, we were able to 
perform several planned sensitivity analyses to assess the robustness of the findings and 
subgroup analyses to investigate potential sources of heterogeneity. These analyses did not 
contradict our main findings. 
 
Third, the primary focus of this review was to evaluate MRI-TB as a replacement test [102] 
for systematic biopsy. We acknowledge that a strategy of using targeted biopsies as an 
additional test to systematic biopsy increases significant cancer detection, but note that it 
would also increase the detection of clinically insignificant disease. Identifying men with 
clinically important disease and avoiding the overdetection of clinically unimportant disease 
are both critical issues and there is no certainty as to where the optimal balance lies. 
Previous studies suggest that effort should be made to avoid the diagnosis of men with 
clinically unimportant disease who can otherwise be over treated and experience side 
effects of treatment [9-12]. The data presented in this study allow clinicians and patients to 
make informed decisions about the risks and benefits using MRI-TB as a replacement test or 
additional test to systematic biopsy.  
 
Fourth, it is important to appreciate that the majority of centres conducting these studies 
are likely to be those with greater expertise in MRI-TB. Despite this, it is not known what the 
true quality of the MRI conduct, reporting and biopsy is at each centre. High detection rates 
of cancer by MRI-TB are dependent on high quality MRI so it is essential that centres wishing 
to adopt MRI-TB conduct high quality MRI, accurate MRI-TB and have clinicians with 
appropriate training performing these procedures. Minimum standards for MRI conduct and 
reporting have been recommended and should be adhered to [103-105]. Non-expert 
centres can optimise their prostate MRI imaging and reporting under the supervision of a 
centre experienced in prostate MRI. Further, centres using MRI should counsel patients, 
who are considering whether or not to undergo prostate biopsy, with the rates of detection 
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of clinically significant cancer from different MRI levels of suspicion at their centre. Centres 
should be confident about the negative predictive value of MRI at their own centre before 
considering omitting systematic biopsy.  
 
In conclusion, this systematic review highlights that in men with clinical suspicion of 
prostate cancer, MRI-TB detects more clinically significant cancer and less clinically 
insignificant cancer than systematic biopsy and requires fewer biopsy cores. Thus, MRI-TB is 
an attractive alternative diagnostic strategy to systematic biopsy for the diagnosis of 
prostate cancer.  
 17 
Take Home message 
In men with suspected prostate cancer, MRI-targeted biopsy detects more clinically 
significant and less clinically insignificant cancer and requires fewer cores than systematic 
biopsy. 
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Figure 1 – Preferred reporting items for systematic reviews and meta-analysis (PRISMA) 
flow chart 
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Figure 2 – Forest plot of the detection ratio of MRI-targeted biopsy (MRI-TB) versus 
systematic biopsy (SB) for clinically significant cancer (CsPCa) 
 
The forest plot shows 56 study cohorts. Studies are grouped by type of comparator and 
sorted according to type of MRI TB, coil strength and study identifier. Alphabetical suffixes 
were used to identify studies where a first author published multiple papers of non-
overlapping cohorts in the same year. DR = detection ratio. TRUS = transrectal ultrasound 
guided prostate biopsy. Template = transperineal template prostate biopsy. Cognitive = 
cognitive / visual registration; fusion = MRI/US image fusion; In-bore = carried out in the 
MRI scanner; Mixed = more than one registration method used in the study. The pooled 
summary estimate indicated that MRI-TB detected more men with clinically significant 
cancer than systematic biopsy (DR 1.16 [95% CI 1.09-1.24], p < 0.0001). 
 
 
Figure 3 – Forest plot of the detection ratio of MRI-targeted biopsy (MRI-TB) versus 
systematic biopsy (SB) for clinically insignificant cancer (CiPCa) 
 
The forest plot shows 46 study cohorts. Studies are grouped by type of comparator and 
sorted according to type of MRI-TB, coil strength and study identifier. Alphabetical suffixes 
were used to identify studies where a first author published multiple papers of non-
overlapping cohorts in the same year. The pooled summary estimate indicates that MRI-TB 
detected fewer men with clinically insignificant cancer than systematic biopsy, DR 0.66 [95% 
CI 0.57-0.76], p < 0.0001.  
 
 
Figure 4a - Forest plot of the detection ratio for significant cancer detection (csPCa) for 
randomized controlled trials (RCTs) involving MRI-targeted biopsy (MRI-TB) and systematic 
biopsy (SB).  
 
The forest plot shows 8 RCTs. Studies are grouped by study identifier and similarities in the 
index test (MRI-TB +/- additional biopsy) and comparator arm (systematic biopsy +/- 
additional biopsies). Where men with a non-suspicious MRI undergo systematic biopsy, the 
number with clinical significant prostate cancer are reported. Due to clinical heterogeneity 
of the included trials, meta-analysis was only carried out for the subset of 5 RCTs with 
similar index tests and comparators.  
 
 
 
 
  
 
 
 
Figure 4b - Forest plot of the detection ratio for insignificant cancer detection (ciPCa) for 
randomized controlled trials (RCTs) involving MRI-targeted biopsy (MRI-TB) and systematic 
biopsy (SB).  
 
The forest plot shows 8 RCTs. Studies are grouped by study identifier and similarities in the 
index test (MRI-TB +/- additional biopsy) and comparator arm (systematic biopsy +/- 
additional biopsies). Due to clinical heterogeneity of the included trials, meta-analysis was 
only carried out for the subset of 4 RCTs with similar index tests and comparators.  
 
 
 
 
Table 1a: Characteristics of included studies with paired data  
Author (ref) Year Population  N° of patients 
Median 
age 
(years) 
Median 
PSA (ng/ml) 
Median prostate 
volume (cc) 
Positive 
MRI 
Field of 
strength 
(Tesla) 
MRI 
sequences 
Endorectal 
coil 
Threshold for 
target 
Target approach 
(cores per target) 
Comparator 
(cores) 
Definition of clinically 
significant PCa 
Abdi et al. [19] 2015 Prior negative biopsy 86 65.4 10.9 48 86 1.5 T2, DWI, DCE No PI-RADS ≥ 3 Fusion-TBx (2) TRUS-Bx (12) 
Gleason >6 or > 2 cores, and > 
50% of each core 
Arsov et al. ‡ [20] 2015 Prior negative biopsy 210 68 10.8 60 104 3 T2, DWI, DCE No NR In-bore TBx (2) 
TRUS-Bx (12) 
+ fusion-TBx GS ≥ 3+4 
Baco et al. ‡ [21] 2016 Biopsy naive 175 65 7.3 42 63 1.5 T1, T2, DWI No PI-RADS ≥ 3 Fusion-TBx (2) 
TRUS-Bx (12) 
+ targeted 
core to 
palpable 
lesions 
GS = 6 and MCCL ≥ 5 or GS ≥ 7 
Baco et al. [22] 2015 
Biopsy naïve + 
prior negative 
biopsy + prior 
positive biopsy 
135 64 8.7 38.4 128 1.5/3 T2, DWI, DCE No PI-RADS ≥ 3 Fusion-TBx (NR) Prostatectomy 
GS 6 volume ≥ 0.5ml and any GS 
≥ 7 
Bansal et al. [23] 2017 Biopsy naïve 96 64.4 8.6 41 NR 3 T2, DWI, DCE, MRSI No NR Fusion-Bx (NR) TRUS-Bx (12) NR 
Belas et al.[24] 2012 
Prior negative 
biopsy +  prior 
positive biopsy 
71 66 7 45 37 1.5 T2, DWI, DCE No NR Visual-TBx (3) TRUS-Bx (NR) NR 
Boesen et al. [25] 2017 Biopsy negative 206 65 12.8 NR 189 3 T2, DWI, DCE No PI-RADS ≥ 2 Fusion-TBx (1-2) TRUS-Bx (10) GS ≥ 7 
Borkowetz et al. [26] 2015 
Biopsy naïve + 
prior negative 
biopsy 
263 66 8.3 50 263 3 T2, DWI, DCE No PI-RADS ≥ 2 Fusion-TBx (8.9*) TRUS-Bx (12) 
GS > 6 or GS = 6 with 50% 
involvement of PCa in more 
than two cores 
Borkowetz et al. [27] 2017 
Biopsy naïve + 
prior negative 
biopsy + prior 
positive biopsy 
625 66 8.17 50 625 3 T2, DWI, DCE No PI-RADS ≥ 2 Fusion-TBx (7) TRUS-Bx (12) GS ≥ 7 
Brock et al. [28] 2015 Prior negative biopsy 168 64 9.2 55.4 144 3 T2, DWI, DCE No 
PI-RADS ≥ 8 (15 
points) Fusion-TBx (2.3*) TRUS-Bx (12) GS ≥ 7 
Costa et al. [29] 2013 Prior negative biopsy 38 64 14.4 NR 22 3 T2, DCE Yes Likert ≥ 3/4 Visual-TBx (NR) TRUS-Bx (NR) Epstein grading 
Chen et al. [30] 2015 Biopsy naïve 420 NR 9.73 44.82 420 3 T2, DWI No Likert ≥ 3 Visual-TBx (NR) 
Transperineal 
template-Bx 
(12) 
NR 
Cool et al. [31] 2016 
Biopsy naïve + 
prior negative 
biopsy 
100 NR NR NR 78 3 T2, DWI, DCE Yes NR Fusion-TBx (1-3**) TRUS-Bx (12) GS ≥ 7 
De Gorski et al. [32] 2015 Biopsy naïve 232 64 6.5 47 232 1.5 NR No Likert ≥ 2 Fusion-TBx (2-3**) TRUS-Bx (12) 
At least 1 core with a Gleason 
score of 7 (3 + 4) or 6 with a 
maximum cancer core length of 
4 mm or greater 
Delongchamps et al.[33] 2015 Prior positive biopsy 125 65 7.2 40 125 1.5 T2, DWI, DCE Yes NR Fusion-TBx (2) 
Prostatectom
y NR 
Delongchamps et al.[34] 2016 Biopsy naïve 108 65 7.2 46 108 1.5/3 T2, DWI, DCE Yes PI-RADS ≥ 3 Fusion-TBx (3) TRUS-Bx (12) GS ≥ 7 or GS = 6 and MCCL ≥ 5mm 
Distler et al. [35] 2017 
Biopsy naïve + 
prior negative 
biopsy 
1040 65 7.2 45 696 3 T2, DWI, DCE No PI-RADS ≥ 3 Fusion-TBx (3) 
Transperineal 
template-Bx 
(24) 
GS ≥ 7 
Filson et al. [36] 2016 
Biopsy naïve + 
prior negative 
biopsy + prior 
positive biopsy 
1042 NR NR NR 825 3 T2, DWI, DCE No PI-RADS ≥ 3 Fusion-TBx (NR) TRUS-Bx (12) GS ≥ 7 
Frye et al^. [37] 2017 Prior positive biopsy  166 NR NR NR 166 3 T2, DWI, DCE Yes NR Fusion-TBx (2) TRUS-Bx (12) GS ≥ 7 
Garcia Bennet et al.[38] 2015 
Biopsy naïve + 
prior negative 
biopsy 
53 65 12.6 NR 53 1.5/3 T2, DWI, DCE No PI-RADS ≥ 2 Visual-TBx (3) TRUS-Bx (9) NR 
Gordetsky et al. [39] 2017 Biopsy naïve 191 63.3 9.2 NR 191 NR T2, DWI, DCE NR NR Fusion-TBx (4.8*) TRUS-Bx (12) NR 
Günzel et al. [41] 2017 
Biopsy naïve + 
prior negative 
biopsy 
251 68 8.42 49 251 3 T2, DWI No PI-RADS ≥ 3 Fusion-TBx (3) TRUS-Bx (10) NR 
Haffner et al. [40] 2011 Biopsy naïve 555 64 6.75 46 351 1.5 T2, DCE No 
Suspicious vs 
non-suspicious 
(no scoring 
system) 
Visual-TBx (3.8*) TRUS-Bx (10) 
Any MRI lesions biopsied which 
were positive for cancer 
irrespective of Gleason score. 
Or any other biopsy with >5mm 
total cancer length and/or 
gleason pattern >3 
Hansen et al. [42] 2016 Prior negative biopsy 487 66 9 56 343 1.5/3 T2, DWI, DCE No PI-RADS ≥ 3 Fusion-TBx (3) 
Transperineal 
template-Bx 
(24) 
GS ≥ 7 
Jambor et al. [43] 2015 Biopsy naïve 55 nR NR NR 39 3 T2, DWI, DCE, MRSI No PI-RADS ≥ 4 Visual-TBx (1-2**) TRUS-Bx (12) 
3mm core length of Gleason 
3+3 or any Gleason grade 4 
Jang et al. [44] 2015 Prior negative biopsy 42 65 9.77 39.5 NA 3 T2, DWI, DCE No NR Visual-TBx (NR) TRUS-Bx (12) 
GS > 6 or GS 6 with > 50% PCa 
per core or > 2 cores 
Jelidi et al. [45] 2017 
Biopsy naïve + 
prior negative 
biopsy 
130 62.9 9.5 45.9 130 3 T2, DWI, DCE Yes PI-RADS ≥ 2 Fusion-TBx (2-3**) TRUS-Bx (16) GS > 7 or GS = 6 with a CCL > 5 mm 
Junker et al. [46] 2015 Prior negative biopsy 50 63.7 7.6 49.2 50 3 T2, DWI, DCE No PI-RADS ≥ 3 Fusion-TBx (4.5*) TRUS-Bx (10) NR 
Kanthabalan et al. [47] 2016 Prior biopsy positive 77 70.5 14 NR 77 1.5T T2, DWI, DCE No Likert ≥ 3 Visual-TBx (4.9*) 
Transperineal 
template-Bx 
(31) 
GS ≥ 3+4 and/or maximum 
cancer core length (MCCL) ≥4 
mm 
Kasivisvanathan et al. 
[48] 2013 
Biopsy naïve + 
prior negative 
biopsy + prior 
positive biopsy 
182 63.3 6.7 40.6 182 1.5T/3 T2, DWI, DCE No Likert ≥ 3 Visual-TBx (5) 
Transperineal 
template-Bx 
(30) 
GS ≥ 3+4 and/or maximum 
cancer core length (MCCL) ≥4 
mm 
Kaufmann et al. [49] 2015 Prior negative biopsy 287 66 9.7 52 234 1.5 T2, DWI, DCE Yes NR In-bore TBx (2-5**) 
Transperineal 
template-Bx 
(24) 
GS ≥ 7 
Kroenig et al. [50] 2016 Prior negative biopsy 52 66 8.75 49.3 52 NR 
T2, DWI, DCE 
(partially No PI-RADS ≥ 2 Fusion-TBx (10.3*) 
Transperineal 
template-Bx 
(32) 
GS ≥ 7 
Author (ref) Year Population  N° of patients 
Median 
age 
(years) 
Median 
PSA (ng/ml) 
Median prostate 
volume (cc) 
Positive 
MRI 
Field of 
strength 
(Tesla) 
MRI 
sequences 
Endorectal 
coil 
Threshold for 
target 
Target approach 
(cores per target) 
Comparator 
(cores) 
Definition of clinically 
significant PCa 
Kuru et al. [51] 2013 Prior negative biopsy 347 65.3 9.85 48.7 253 3 
T2, DWI, DCE, 
MRSI No 
Suspicious vs 
non-suspicious 
(no scoring 
system) 
Fusion-TBx (NR) TRUS-Bx (12-6) NR 
Lacetera et al. [52] 2016 
Biopsy naïve + 
prior negative 
biopsy 
22 64 7.7 55 22 1.5 T2, DWI No PI-RADS ≥ 3 Fusion-TBx (3) TRUS-Bx (12) GS ≥ 7 
Lai et al. [53] 2017 Prior positive biopsy 76 62.5 5.1 NR 76 3 T2, DWI, DCE No PI-RADS ≥ 3 Fusion-TBx (2.3*) TRUS-Bx (12) GS ≥ 7 
Lawrence et al. [54] 2014 Prior negative biopsy 39 64 10 NR 39 1.5/3 T2, DWI No 
Suspicion score ≥ 
6/10 Fusion-TBx (7) 
TRUS-Bx (24-
36) GS ≥ 7 
Lian et al. [55] 2017 Prior negative biopsy 101 68.9 10.8 42.1 101 3 T2, DWI, DCE No PI-RADS ≥ 2 Fusion-TBx (4.9*) 
Transperineal 
template-Bx 
(12) 
GS ≥ 7 or GS 6 with MCCL ≥ 4 
mm 
Ma et al.^ [56] 2017 
Biopsy naïve + 
prior positive 
biopsy 
230 NR NR NR 230 3 T2, DWI, DCE Yes PI-RADS ≥ 3 Fusion-TBx (3-4) TRUS-Bx(12) GS ≥ 7 
Mariotti et al. [57] 2016 
Biopsy naïve + 
prior negative 
biopsy 
389 NR NR NR 389 3 T2, DWI, DCE Yes Likert ≥ 3 Fusion-TBx (2-3) TRUS-Bx (12) 
GS 3 + 4 with 50% or more of 
any core positive for cancer or 
33% or more of standard biopsy 
cores positive for cancer or GS 4 
+ 3 or greater cancers 
Mariotti et al. [58] 2017 
Biopsy naïve + 
prior negative 
biopsy 
100 62.5 5.3 48 100 3 T2, DWI, DCE No Likert ≥ 3 Fusion-TBx (2-3**) TRUS-Bx (12) GS ≥ 7 
Maxeiner et al. [59] 2015 
Biopsy naïve + 
prior negative 
biopsy 
169 65.6 13.9 60.6 NR 3 T2, DWI No PI-RADS ≥ 2 Fusion-TBx (1.86*) TRUS-Bx (10) Gleason ≥ 4+3 
Mendhiratta et al. [60] 2015a Biopsy negative 161 64.9 8.9 72.5 161 3 T2, DWI, DCE No NR Fusion-TBx (NR) TRUS-Bx (12) GS ≥ 7 
Mendhiratta et al. [61] 2015b Biopsy naïve 382 64.5 6.8 44 382 3 T2, DWI, DCE No Likert ≥ 2 Fusion-TBx (5.7*) TRUS-Bx (12) GS ≥ 7 
Meng et al. [62] 2016 
Biopsy naïve + 
prior negative 
biopsy + prior 
positive biopsy 
601 65.2 6.7 59.9 601 3 T2, DWI, DCE No Likert ≥ 2 Fusion-TBx (4) TRUS-Bx (12) GS ≥ 7 
Mozer et al. [63] 2014 Biopsy naïve 152 63 6 44 152 1.5 T2, DWI, DCE No Likert ≥ 2 Fusion-TBx (2) TRUS-Bx (12) 
At least one core with a Gleason 
score of 3 + 4 or 6 with a 
maximum cancer core length ≥4 
mm 
Okoro et al. [64] 2015 Prior positive biopsy 50 61.4 5.34 NR 50 3 
T2, DWI, DCE, 
MRSI Yes NR Fusion-TBx (1) TRUS-Bx (12) NR 
Panebianco et al. ‡ [5] 2015 Biopsy naïve 1140 NR NR NR NR 3 T2, DWI, DCE Yes PI-RADS ≥ 2 Visual-TBx  (2) TRUS-Bx (12) 
 
GS ≥ 3+4 
 
Peltier et al. [65] 2015 Biopsy naïve 110 65.1 8.4 49.3 110 3 T2, DWI, DCE, MRSI Yes NR Fusion-TBx (2.4*) 
TRUS-Bx 
(14.6) GS ≥ 7 and/or MCCL ≥ 6mm 
Pepe et al. [66] 2016a Biopsy positive 75 NR NR NR 31 3 T2, DWI, DCE, MRSI Yes PI-RADS ≥ 3 Fusion-TBx (4) 
Transperineal 
template-Bx 
(NR) 
GS ≥ 7 and/or number of cores 
positive>2 
Pepe et al. [67] 2016b Prior negative biopsy   200 NR 8.6 NR 60 3 
T2, DWI, DCE, 
MRSI Yes PI-RADS ≥ 4 Fusion-TBx (4) 
Transperineal 
template-Bx 
(30) 
GS ≥ 7 and/or number of cores 
positive > 2 
Pessoa et al. [68] 2017 Prior positive biopsy 105 67 7.5 53 87 3 T2, DWI, DCE No PI-RADS ≥ 2 Fusion-TBx (2-6**) TRUS-Bx (12) 
GS ≥ 7 and/or core involvement 
>50% 
Pokorny et al. [69] 2014 Biopsy naïve 223 63 5.3 41 142 3 T2, DWI, DCE No PI-RADS ≥ 3 In-bore TBx (2) TRUS-Bx (12) 
(i) GS 3+3 in > 2 cores    or  
(ii) GS 3+3 >6mm in 1 core    or 
(iii) GS 3+4 > 4mm in ≥ 1 core  or 
(iv) GS 3+4 in ≥ 2 cores.  
Puech et al. [70] 2013 
Biopsy naïve + 
prior negative 
biopsy 
95 65 10.1 52 95 1.5 T2, DWI, DCE No Likert ≥ 13 or ≥ 5 Fusion-TBx (1.5*) TRUS-Bx (12) Gleason ≥ 3+4; MCCL ≥ 3 mm 
Quentin et al. [71] 2014 Biopsy naïve 128 66 8.7 54.7 128 3 T2, DWI, DCE No NR In-bore TBx (2) TRUS -Bx(12) Gleason ≥ 3+4 
Reed et al. [72] 2017 Prior positive biopsy 73 NR NR NR 73 3 T2, DWI, DCE Yes NR Fusion-TBx (6) TRUS-Bx (12) NR 
Salami et al. [73] 2015 Biopsy negative 140 NR NR NR 140 3 T2, DWI, DCE Yes NR Fusion-TBx (NR) TRUS-Bx (12) 
Gleason ≥ 3+4 or Gleason 3+3 
MCCL 50% or more than 2 cores 
positive 
Shigemura et al. [74] 2012 Biopsy naïve + prior negative 96 67 8.58 31.9 96 1.5 
T2, DWI, DCE 
(partially) NR 
Suspicious vs. 
non-suspicious Fusion-TBx (NR) TRUS-Bx (12) NR 
Shin et al. [75] 2017 
Biopsy naïve + 
prior negative 
biopsy + prior 
positive biopsy 
117 63 7.1 52.9 117 3 NR NR NR Fusion-TBx (NR) TRUS-Bx (10-12) GS ≥ 7 
Shoji et al. [76] 2015 Biopsy naïve 20 70 7.4 38 20 1.5 T2, DWI, DCE No PI-RADS ≥ 2 Fusion-TBx (NR) 
Transperineal 
template 
biopsy (12) 
Gleason ≥ 3+4 OR (Gleason 6 + 
MCCL≥4mm) 
Siddiqui et al. [77] 2015 
Biopsy naïve + 
prior negative 
biopsy 
1003 62.1 6.7 49 1003 3 T2, DWI, DCE, MRSI Yes Score ≥ 1 Fusion-TBx (6.2*) TRUS-Bx (12) Gleason ≥ 4+3 
Sonn et al. [78] 2014 
Biopsy naïve + 
prior negative 
biopsy 
105 65 7.5 58 101 3 T2, DWI, DCE No NR Fusion-TBx (NR) TRUS-Bx (12) 
Gleason 3 + 4 or Gleason 6 with 
maximal cancer core length 
(MCL) ≥4mm 
Tontilla et al. ‡ [79] 2016 Biopsy naïve 113 63 6.1 27.8 40 3 T2, DWI, DCE No Likert ≥ 2/4 Visual-TBx (2) TRUS-Bx (10-12) Gleason ≥ 3+4 
Tran et al. [80] 2016 Prior positive biopsy 207 66.7 5.9 42 207 3 T2 Yes NR Fusion-TBx (2) TRUS-Bx (14) NR 
Ukimura et al. [81] 2015 
Biopsy naïve + 
prior negative 
biopsy 
127 66 5.8 NR 127 3 T2, DWI, DCE No NR Fusion-TBx (2.8*) TRUS-Bx (11) GS ≥ 7 and/or maximum cancer 
core length ≥5 mm 
Valerio et al. [82] 2015 Biopsy naïve + prior negative 50 68 7.9 38 50 1.5/3 T2, DWI, DCE No Likert ≥ 3 Fusion-TBx (3) 
Transperineal 
template-Bx 
GS ≥ 3 + 4 and/or maximum 
cancer core length ≥4 mm 
Author (ref) Year Population  N° of patients 
Median 
age 
(years) 
Median 
PSA (ng/ml) 
Median prostate 
volume (cc) 
Positive 
MRI 
Field of 
strength 
(Tesla) 
MRI 
sequences 
Endorectal 
coil 
Threshold for 
target 
Target approach 
(cores per target) 
Comparator 
(cores) 
Definition of clinically 
significant PCa 
biopsy + prior 
positive biopsy 
(32) 
Volkin et al. [83] 2014 
Biopsy naïve + 
prior negative 
biopsy 
42 64 12.6 53.5 42 3 T2, DWI, DCE, MRSI Yes Score ≥ 1 Fusion-TBx (NR) TRUS-Bx (12) NR 
von Below et al. [84] 2017 
Biopsy naïve + 
prior positive 
biopsy 
53 64 6.4 33 53 3 T2, DWI, MRSI Yes Likert > 1 Fusion-TBx (2) TRUS-Bx (12) GS ≥ 7 
Wang et al. [85] 2016 Biopsy negative 15 NR NR NR 15 NR NR NR NR Fusion-TBx (NR) TRUS-Bx (NR) NR 
Wysock et al. [86] 2014 
Biopsy naïve + 
prior negative 
biopsy + prior 
positive biopsy 
125 65 5.1 40.5 67 3 T2, DWI, DCE No PI-RADS ≥ 2 Fusion-TBx (2) TRUS-Bx (NR) NR 
Zhang et al. [87] 2014 Biopsy naïve 518 NR NR NR 254 3 T2, DWI, DCE, MRSI No 
Suspicious vs. 
non-suspicious Fusion-TBx (NR) TRUS-Bx (12) NR 
Zhang et al. [88] 2017 Biopsy naïve 224 69 10.05 45.5 224 3 T2, DWI, DCE No Likert ≥ 2 Fusion-TBx (3.54*) Transperineal-Bx (12) 
GS > 6 or GS 6 with 50% 
involvement of PCa per core 
Zhang et al. [89] 2015 Biopsy naïve 62 68.38 10.21 34.05 62 3 T2, DWI, DCE No PI-RADS ≥ 2 Fusion-TBx (3.24*) Transperineal-Bx (12) 
GS of 7 (or more) or 6 with a 
MCCL > 4 mm 
* Mean; ** Range; GS: gleason score; TBx: MRI targeted prostate biopsy; TRUS: transrectal ultrasound guided prostate biopsy; ^Represents a combination of cohorts by the same author. ‡Represents paired data from an arm of a randomized controlled trial    
Table 1b: Characteristics of randomized controlled trials  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GS: Gleason score; MCCL: maximum score length; PCa: prostate cancer; csPCa: clinically significant prostate cancer; TBx:  Targeted biopsy 
Author, ref Year Population investigated 
N° of 
patients 
Investigation arm, 
(N) 
Comparator arm, 
(N) 
Sequences and 
coil strength Threshold for target 
Definition of clinically 
significant PCa Key findings 
Arsov et al. [20] 2015 Prior negative biopsy 210 
In Bore-TBx 
(106) 
MRI-fusion-TBx + 
12-core TRUS-Bx 
(104) 
T1, T2, DWI, DCE, 
3T NR GS ≥ 3+4 
I) No significant differences between combined 
biopsy approach over In Bore-TBx alone 
II) Only difference that fewer number of cores 
were taken in In Bore-TBx alone patients 
Baco et al. [21] 2016 Biopsy naïve  175 
MRI-fusion-TBx + 
12-core  TRUS-Bx 
(86) 
12-core TRUS-Bx + 
target core on 
palpable lesions 
(89) 
T1, T2, DWI, 1.5T PI-RADS ≥ 3 GS = 6 and MCCL ≥ 5 or GS ≥ 7 
I) Overall csPca detection rate was similar 
between the two groups 
II) Traditional 12-core TUR-Bx may be replaced 
by two-core MRI-TBx 
Kasivisvanathan et al. [1] 2018 Biopsy naïve 500 MRI + MRI-TBx in  MRI positive 
10-12 core TRUS-
Bx 
T1, T2, DWI, DCE 
1.5T/3T PI-RADS ≥ 3 GS ≥ 3+4 
The proportion of men with clinically 
significant cancer in the MRI arm was greater 
than TRUS-Bx and the proportion of men with 
clinically insignificant cancer was less in the 
MRI arm than tha TRUS-Bx arm 
Panebianco et al. [5] 2015 Biopsy naïve  1140 
TRUS-Bx + MRI-TBx 
in positive MRI 
(570) 
12-core TRUS-Bx 
(570) 
T1, T2, DWI, DCE 
3T PI-RADS ≥ 2 GS ≥ 3+4 
The proportion of men with csPCa is higher 
among those randomized to MRI-TBx vs. 
those randomized to TRUS-Bx 
Park et al. [90] 2011 Biopsy naïve  85 
MRI-cognitive-TBx 
+ 10-12-core TRUS-
Bx 
(44) 
10-12-core TRUS-
Bx 
(41) 
T1, T2, DWI, DCE 
3T NR NR 
MRI group had a significant higher detection 
rate of PCa 
Porpiglia et al. [6] 2017 Biopsy naïve  212 
MRI-fusion-TBx 
alone when 
positive MRI; TRUS-
Bx when negative 
MRI 
(107) 
12-core TRUS-Bx 
(105) 
T1, T2, DWI, DCE 
1.5T PI-RADS ≥ 3 
GS ≥ 7 or MCCL ≥ 
5mm 
A diagnostic pathway based on MRI had higher 
detection rate of both PCa and csPCa 
compared to standard pathway  
Taverna et al. [91] 2015 Prior negative biopsy 200 
MRI-cognitive-TBx 
+ 13 core TRUS-Bx 
(100) 
13 core TRUS-Bx 
(100) 
T2 + others (NR) 
3T 
“MRI-positive lesion” 
using PI-RADSv2 GS ≥ 3+4 
No difference in overall cancer detection 
between MRI-TBx and systematic biopsy 
Tonttila et al. [79] 2016 Biopsy naïve  113 
MRI-cognitive-TBx 
+ 10-12-core TRUS-
Bx 
(53) 
10-12-core TRUS-
Bx 
(60) 
T1, T2, DWI, DCE 
3T Likert ≥ 2/4 GS ≥ 3+4 
MRI-TBx did not improve PCa detection rate 
compared with TRUS-Bx alone 
Table 2: A summary of overall and subgroup analyses for the detection of clinically 
significant cancer 
 Study 
cohorts 
(n) 
Number 
of men 
with 
cancer 
DR (95% CI) P value τ2 I2 
(%) 
Overall 56 4652 1.16 (1.09, 1.24) <0.0001 0.040 87 
Clinically significant cancer threshold  
≥ Gleason 3+4 31 3014 1.09 (1.02, 1.18) 0.018 0.027 80 
≥ Gleason 4+3 14 752 1.38 (1.14, 1.68) 0.001 0.082 82 
  
Subgroup analyses and meta-regression  
Type of systematic biopsy  
TRUS biopsy 42 3445 1.22 (1.13, 1.32)  0.045 87 
Template biopsy 14 1207 0.99 (0.91, 1.07)  0.014 77 
Difference    0.083   
  
Prior biopsy status  
Biopsy naïve  19 1548 1.18 (1.06, 1.31)  0.039 87 
Prior biopsy 
negative 
15 896 1.22 (1.05, 1.42)  0.064 84 
Prior biopsy positive 10 493 1.09 (0.92, 1.30)  0.052 77 
Difference    0.71   
 
MRI registration method 
Cognitive 10 895 1.11 (0.94, 1.31)  0.059 92 
Fusion  38 3225 1.22 (1.12, 1.33)  0.050 87 
Difference     0.36   
τ2 is the between study variance, a measure of between study heterogeneity. 
CI = confidence interval; DR = detection ratio; TRUS = transrectal ultrasound-guided. 
Meta-regression was used to formally assess differences between subgroups. 
 
Table 3: A summary of overall and subgroup analyses for the detection of clinically 
insignificant cancer 
 Study 
cohorts 
(n) 
Number 
of men 
with 
cancer 
DR (95% CI) P value τ2 I2 
(%) 
Overall 46 2124 0.66 (0.57, 0.76) <0.0001 0.152 88 
Clinically insignificant cancer threshold  
≥ Gleason 3+3 25 1481 0.74 (0.65, 0.84)   <0.0001 0.069 79 
  
Subgroup analyses and meta-regression  
Type of systematic biopsy  
TRUS biopsy 36 1822 0.64 (0.54, 0.76)  0.175 90 
Template biopsy 10 302 0.74 (0.60, 0.91)    0.055 58 
Difference    0.61   
  
Prior biopsy status  
Biopsy naïve  15 704 0.71 (0.52, 0.96)  0.289 92 
Prior biopsy 
negative 
12 312 0.48 (0.35, 0.66)  0.176 71 
Prior biopsy positive 4 251 0.51 (0.40, 0.66)  0.026 40 
Difference    0.12   
 
MRI registration method 
Cognitive 9 460 0.81 (0.56, 1.17)  0.207 89 
Fusion  31 1593 0.64 (0.56, 0.73)  0.094 83 
Difference     0.14   
τ2 is the between study variance, a measure of between study heterogeneity. 
CI = confidence interval; DR = detection ratio; TRUS = transrectal ultrasound-guided. 
Meta-regression was used to formally assess differences between subgroups. 
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Supplementary Appendix 1 
 
Search terms used in the systematic review 
 
Searches were carried out on 28th July 2017. 
 
Ovid (EMBASE and Medline) 
1     exp Biopsy/ 
2     biopsy.mp. or biopsies.ti,ab.  
3     biopsy.af. 
4     1 or 2 or 3 
5     MRI-TB.ti,ab. 
6     MRI.ti,ab. 
7     MRI*.ti,ab. 
8     exp Magnetic Resonance Imaging/  
9     magnetic resonance imag*.ti,ab.  
10   magnetic resonance imaging.af. 
11    or/5-10  
12    prostate.ti,ab.  
13    ((prostat*) adj2 (neoplasm* or cancer* or carcinoma* or tumor* or tumour*)).ti,ab.  
14    exp Prostatic Neoplasms/  
15    prostate.af. 
16     or/12-15 
17     4 and 11 and 16  
 
Web of Science 
TS=((( biops*)) AND (("magnetic resonance imaging" or MRI)) AND ((prostat*)) AND 
((detection or diag*)))  
 
Cochrane Library 
(biops*):ab,ti and ('magnetic resonance' or mri) and (prostat*):ab,ti  
 
Clinicaltrials.gov 
Search terms included: “Prostate neoplasm” and Other Terms included “MRI, biopsy”. If a 
relevant trial was in progress at the time of the search, the trial contacts specified were 
contacted for study results and if the published paper was available prior to completing data 
extraction on the 8th July 2018, the study results were eligible to be included.  
 
Reference searching 
References of included studies were hand searched and relevant studies meeting eligibility 
criteria of the study were included.  
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Supplementary Appendix 2 
 
The list of variables for which data were collected from studies include: 
 
1. First Author Surname  
2. Year of Publication (YYYY) 
3. Study design (prospective vs retrospective; paired studies, case-control type studies, 
randomised controlled trials, other) 
4. Inclusion and exclusion criteria 
5. Total number of patients (n) 
6. Average age of the patients (years) 
7. Prior biopsy status of population (biopsy naïve, prior positive, prior negative, mixed) 
8. Number of men without prior biopsy (n) 
9. Number of men with prior negative biopsy (n) 
10. Number of men with prior positive biopsy (n) 
11. Number of men with prior treatment to the prostate (n) 
12. Average prostate volume (mls) 
13. Average PSA (ng/ml) 
14. MRI coil strength (1.5T, 3T, other) 
15. MRI machine model (Freetext e.g. Siemens Avanto) 
16. MRI sequences used (T2, T2&DWI, T2&DCE, T2&DWI&DCE, other e.g. MRS) 
17. MRI Coils used (pelvic phased array only, pelvic phased array and endorectal) 
18. Experience of reporting radiologist (years) 
19. Scoring system used for declaring a suspicious lesion (PIRADs, Likert 1-5, other) 
20. Threshold score for declaring a suspicious lesion (1, 2, 3, 4, 5, other) 
21. Number of men with suspicious lesions (n) 
22. Number of men who underwent MRI-targeted biopsy (n) 
23. Sampling route of MRI-TB (transrectal, transperineal, other) 
24. MRI-TB performed first (yes/no) 
25. Order of cores taken randomized (yes/no) 
26. Average number of suspicious lesions per man identified on MRI (n) 
27. Type of systematic biopsy (TRUS-biopsy, transperineal biopsy, other) 
28. What the reference test was (systematic & targeted biopsies together or other) 
29. For MRI-targeted biopsy, the registration method used (visual registration alone, 
software assisted registration or in-bore MRI) 
30. If software assisted, what was the software used? (Freetext e.g. Koelis urostation) 
31. If software assisted used, was there a comparison of more than one method of 
registration (yes/no) 
32. For MRI-targeted biopsy, whether the biopsy operator viewed MRI images, a prose 
report or diagrammatic report (MRI images viewed, prose report viewed, 
diagrammatic report viewed, all) 
33. For MRI-targeted biopsy, modality of real-time guidance during procedure (US, MRI) 
34. Anaesthesia used (LA, GA) 
35. Systematic cores taken blind to location of MRI-suspicious lesions (yes/no) 
36. Average number of targeted cores per patient (n) 
37. Total number of targeted cores taken in whole study (n) 
38. Average number of targeted cores per suspicious lesion (n) 
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39. Total number of systematic cores taken in whole study (n) 
40. Average number of systematic cores taken per patient (n) 
41. Number of men with any cancer detected by MRI-TB (n) 
42. Number of men with any cancer detected by systematic biopsy (n) 
43. Number of men with any cancer detected by both tests (n) 
44. Threshold used to define clinically significant cancer (Freetext e.g. Gleason 7 or 
maximum cancer core length > 4mm) 
45. Number of men with Gleason 6 cancer on MRI-targeted biopsy (n) 
46. Number of men with Gleason 3+4 cancer on MRI-targeted biopsy (n) 
47. Number of men with Gleason 4+3 cancer on MRI-targeted biopsy (n) 
48. Number of men with Gleason 4+4 cancer on MRI-targeted biopsy (n) 
49. Number of men with > Gleason 4+4 cancer on MRI-targeted biopsy (n) 
50. Number of men with clinically significant cancer on MRI-targeted biopsy (n) 
51. Number of men with clinically insignificant cancer on MRI-targeted biopsy (n) 
52. Number of men with clinically significant cancer missed by systematic biopsy 
detected by MRI-TB (n) 
53. Number of men with clinically insignificant cancer missed by systematic biopsy 
detected by MRI-TB (n) 
54. Number of men with Gleason 6 cancer on systematic biopsy (n) 
55. Number of men with Gleason 3+4 cancer on systematic biopsy (n) 
56. Number of men with Gleason 4+3 cancer on systematic biopsy (n) 
57. Number of men with Gleason 4+4 cancer on systematic biopsy (n) 
58. Number of men with > Gleason 4+4 cancer on systematic biopsy (n) 
59. Number of men with clinically significant cancer on systematic biopsy (n) 
60. Number of men with clinically insignificant cancer on systematic biopsy (n) 
61. Number of men with clinically significant cancer missed by MRI-TB detected by 
systematic biopsy (n) 
62. Number of men with clinically insignificant cancer missed by MRI-TB detected by 
systematic biopsy (n) 
63. Number of men with Gleason 6 cancer on reference test (n) 
64. Number of men with Gleason 3+4 cancer on reference test (n) 
65. Number of men with Gleason 4+3 cancer on reference test (n) 
66. Number of men with Gleason 4+4 cancer on reference test (n) 
67. Number of men with > Gleason 4+4 cancer on reference test (n) 
68. Number of men with clinically significant cancer on reference test (n) 
69. Number of men with clinically insignificant cancer on reference test (n) 
70. Total number of cores positive for cancer on MRI-TB 
71. Total number of cores positive for clinically significant cancer on MRI-TB 
72. Total number of cores positive for clinically insignificant cancer on MRI-TB 
73. Total number of cores positive for cancer on systematic biopsy 
74. Total number of cores positive for clinically significant cancer on systematic biopsy 
75. Total number of cores positive for clinically insignificant cancer on systematic biopsy 
76. Total number of cores positive for cancer on reference test 
77. Total number of cores positive for clinically significant cancer on reference test 
78. Total number of cores positive for clinically insignificant cancer on reference test 
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Supplementary Appendix 3 
 
The modified Quality Assessment of Diagnostic Accuracy Studies-2 checklist used for risk of 
bias assessment and applicability concern 
 
Domain 1: Patient selection  
 
A. RISK OF BIAS: Could selection of patients have introduced bias? 
Describe the methods of patient selection briefly: 
 
 
 
Signalling Question (SQ)1: Was a consecutive or random sample of 
patients enrolled? 
 
Yes / No / Unclear 
SQ2: Was a case-control/matched cohort design avoided? 
 
If the study is a paired study (each man gets both tests) or an RCT, 
please answer “Yes” 
If the study is a matched cohort (matched cohort is when a group of 
men under study are compared to another group of men matched by 
specific factors (e.g. age, PSA). This group is usually historic. i.e. the 2 
groups are not collected in the same time period / centre), please 
answer “No” 
 
Yes / No / Unclear 
SQ3: Did the study avoid inappropriate exclusions? 
 
Inappropriate exclusions would be exclusion of patients who are more 
or less likely to have disease which may influence the diagnostic 
accuracy of the test.  
 
Examples of inappropriate exclusions: 
- excluding patients with likely T3/T4 or extremely high PSA 
would be inappropriate 
- including only patients who underwent radical prostatectomy 
- excluding patients with prior negative biopsies (they are not 
including the most difficult to diagnose patients) 
- including only active surveillance patients (includes only 
patients more likely to have a positive test) 
 
Studies that avoid inappropriate exclusions are studies that have been 
as broad as possible in terms of the population included. 
 
Yes / No / Unclear 
SUMMARY: RISK OF BIAS FOR PATIENT SELECTION DOMAIN: 
 
High risk if ‘No’ for at least one SQ 
Low risk if ‘Yes’ for all SQs. 
Low risk / High risk / Unclear risk 
5 
 
Unclear risk if “Unclear” for at least one SQ (though “No” for one SQ 
supersedes “Unclear” if both results present).  
 
B. CONCERNS FOR APPLICABILITY OF PATIENT SELECTION DOMAIN 
Describe briefly the included patients (prior testing, presentation, intended use of index test and setting):  
 
 
 
Are there concerns that the included patients and setting do not match 
the review question? 
 
This is a pragmatic review hence the inclusion criteria are wide. If the 
study includes patients that fulfil the criteria above, this is “Low 
concern”. If it does not, this is “High concern”. If insufficient data are 
reported to make a decision then this is “Unclear concern” 
Low concern / High concern / 
Unclear concern 
 
Domain 2: Index Test  
 
A. RISK OF BIAS: Could the conduct or interpretation of the index test have introduced bias? 
Describe briefly the nature of the MRI-targeted biopsy, how it was conducted and results interpreted: 
 
 
 
SQ1: Was the MRI-targeted biopsy performed without knowledge of the 
results of the comparator/systematic biopsy? 
 
If both biopsy tests were done in the same sitting, it is usually not 
possible to know the results of the systematic biopsy in which case 
answer “Yes”. 
Yes / No / Unclear 
SQ2:  Was the MRI-targeted biopsy conducted independently of the 
conduct of the systematic biopsy?  
 
For example, if the systematic biopsy sampled a particular area in the 
prostate, would that influence where the MRI-targeted biopsy sampled? 
If yes then answer “No”   
Yes / No / Unclear 
SQ3: Was the MRI score / risk threshold for patients to undergo 
targeted biopsy pre-specified? 
Yes / No / Unclear 
SUMMARY: RISK OF BIAS FOR INDEX TEST: 
High risk if ‘No’ for at least one applicable SQ 
Low risk if ‘Yes’ for all applicable SQs. 
Unclear risk if “Unclear” for at least one applicable SQ. (Though “No” for 
one SQ supersedes “Unclear” if both results present). 
Low risk / High risk / Unclear 
risk 
 
B. CONCERNS FOR APPLICABILITY  
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Are there concerns that the index test, its conduct, or interpretation 
differ from the review question?  
 
This is a pragmatic review hence the different types of targeted biopsy 
(i.e. cognitive/software fusion/in bore targeted biopsy) admissible are 
wide.  
If the study described the type of MRI-targeted biopsy in detail, this is 
“Low concern”. If it did not, this is “High concern”. In addition, if more 
than one type of targeted biopsy was conducted in the intervention arm 
and results cannot be separated for each type, then this should be 
categorised as “High concern”. If insufficient data are reported to make 
a decision then this is “Unclear concern”. 
Low concern / High concern / 
Unclear concern 
 
 
Domain 3: Comparator test (Systematic biopsy (TRUS-biopsy, Transperineal template biopsy, or variations 
of these) or Radical prostatectomy)  
 
A. RISK OF BIAS: Could the conduct or interpretation of the comparator test have introduced bias? 
Describe briefly the nature of the comparator test, how it was conducted and results interpreted: 
 
 
 
SQ1: Was the systematic /comparator biopsy performed without 
knowledge of the results of the MRI-targeted biopsy? 
 
If both biopsy tests were done in the same sitting, it is usually not possible 
to know the results of the systematic biopsy in which case answer “Yes”. A 
radical prostatectomy (if the only comparison) would be answered “No”. 
Yes / No / Unclear 
SQ2:  Was the systematic /comparator biopsy conducted independently of 
the conduct of the systematic biopsy?  
 
To answer this question consider both of the following: 
1. For example, if the MRI-targeted-biopsy sampled a particular area 
in the prostate, would that influence where the systematic biopsy 
sampled? If yes then answer “No”. If not stated, say “Unclear” 
2. Was the systematic biopsy operator blinded to the MRI report? If 
not, answer “No”. If not stated, say “Unclear” 
 
If 1) or 2) is “No”, this overrules “Unclear”. 
 
Yes / No / Unclear 
SUMMARY: RISK OF BIAS FOR COMPARATOR TEST: 
High risk if ‘No’ for at least one applicable SQ 
Low risk if ‘Yes’ for all applicable SQs. 
Unclear risk if “Unclear” for at least one applicable SQ. (Though “No” for 
one SQ supersedes “Unclear” if both results present). 
Low risk / High risk / Unclear 
risk 
 
B. CONCERNS FOR APPLICABILITY  
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Are there concerns that the comparator test, its conduct, or interpretation 
differ from the review question? 
 
Does the study pre-specify definition of clinically significant cancer by the 
comparator test? If yes, is “Low risk”. If it does not, this is “High risk”. If 
insufficient data are reported to make a decision then this is “Unclear” 
Low concern / High concern 
/ Unclear concern 
 
 
Domain 4: Flow and Timing  
 
A. RISK OF BIAS: - Could the patient flow have introduced bias? 
Describe any patients who did not receive the index or comparator test, or who were excluded from 
the analysis. Describe the interval and any interventions between the index and comparator tests. 
 
 
SQ1: Was the time interval between any of the following combinations of 
tests less than 6 months? 
● mpMRI and MRI targeted biopsy 
● MRI targeted biopsy and systematic biopsy / radical prostatectomy 
Yes / No / Unclear 
SQ2: Did all patients receive the same comparator test?  
 
N.B. If a sub-group of patients received radical prostatectomy, this is ok, 
providing the whole cohort first received the same systematic biopsy 
technique (TRUS-biopsy OR transperineal template prostate biopsy) 
Yes / No / Unclear 
SQ3:  Were all patients who underwent testing included in the analysis? 
 
Please look out for withdrawal numbers and lost to follow-up patients 
within each study arm: is the number of patients significantly different 
between arms? If there are imbalances between arms, please answer “No” 
   
Yes / No / Unclear 
SUMMARY: COULD THE PATIENT FLOW HAVE INTRODUCED BIAS: 
High risk if ‘No’ for at least one SQ 
Low risk if ‘Yes’ for all SQs. 
Unclear risk if “Unclear” for at least one SQ. (Though “No” for one SQ 
supersedes “Unclear” if both results present). 
Low risk / High risk / Unclear 
risk 
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Supplementary Appendix 4 
 
Further details on data synthesis methods 
The table below shows the cross classification of the results of MRI-TB and systematic 
biopsy for the primary outcome of clinically significant cancer in a paired study.  
 Systematic biopsy  
Significant cancer  No significant cancer Total 
M
RI
-T
B Significant cancer  a b a + b 
No significant cancer  c d c + d 
 Total a + c b + d a + b + c + d 
 
The detection ratio (DR) is the ratio of the MRI-TB detection rate divided by the systematic 
biopsy detection rate. Thus, using the notation in the table above, the DR was calculated as 
a+b
a+c
.  To account for the correlated data, the within-study variance of the natural log of the 
detection ratio, V[ln(DR)], in a study was calculated as 
(b+c)(a+c)(a+b) . We then used the 
inverse variance weighted approach to obtain the pooled ln(DR) and its 95% confidence 
interval (CI). These estimates were then exponentiated to obtain the pooled DR and its 95% 
CI. Similar analyses were performed to obtain pooled estimates for clinically insignificant 
cancer and for any cancer. 
 
For RCTs we constructed a 2x2 table by cross classifying the outcome against the 
randomized groups. For example, the table below represents the results of an RCT of MRI-
TB versus systematic biopsy. 
 MRI-TB group Systematic biopsy group Total 
Significant cancer  a b a + b 
No significant cancer c d c + d 
Total a + c b + d a + b + c + d 
We computed the proportion in each group, e.g. a/(a +c) for MRI-TB and b/(b + d) for 
systematic biopsy, and compared proportions between randomized groups to obtain the 
detection ratio. When there were studies that used the same index test and comparator, we 
performed random effects meta-analysis using the DerSimonian and Laird approach1.  
 
For the additional analyses, we compared the proportion of cores positive for prostate 
cancer by MRI-TB with that of systematic biopsy, and pooled the ratio (relative risk) in a 
random effects meta-analysis using the method of DerSimonian and Laird. We pooled 
proportions using a random effects meta-analysis with the Freeman-Tukey double arcsine 
transformation. 
  
References 
1DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88. 
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5a: Risk of bias assessment and applicability concern in included studies according to a 
modified Quality Assessment of Diagnostic Accuracy Studies-2 checklist: 
Low Low risk 
High High risk 
Unclear Unclear risk 
 
Study 
Risk of bias   Applicability concern   
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Abdi 2015 High risk Low risk Low risk Unclear risk 
 
Low concern High concern Low Concern   
Arsov 20151 Low risk Low risk Low risk Low risk 
 
Low concern Low concern Low Concern   
Baco 2015 Low risk Unclear risk Low risk High risk 
 
Low concern High concern Low Concern   
Baco 20161 High risk Low risk Low risk Low risk 
 
High concern Low concern Low Concern   
Bansal 2017 Low risk High risk Unclear risk Unclear risk 
 
Low concern Low concern Low  Concern   
Belas 2012 High risk Unclear risk Unclear risk Unclear risk 
 
Low concern High concern Low Concern   
Boesen 2017 Unclear risk Low risk High risk Unclear risk 
 
Low concern Low concern Low Concern   
Borkowetz 2015 Low risk Low risk Low risk Low risk 
 
Low concern Low concern Low Concern   
Borkowetz 2017 Low risk Low risk Low risk Unclear risk 
 
Low concern Low concern Low  Concern   
Brock 2015 Unclear risk Low risk Low risk Low risk 
 
Low concern Low concern High Concern   
Chen 2015 Low risk Low risk Low risk Low risk 
 
Low concern Low concern Low Concern   
Cool 2016 High risk High risk Low risk High risk 
 
High concern High concern Low  Concern   
Costa 2013 Unclear risk Low risk Low risk High risk 
 
Low concern High concern Low Concern   
De Gorski 2015 Low risk Low risk Low risk Low risk 
 
Low concern Low concern Low  Concern   
Delongchamps 2015 High risk High risk High risk Unclear risk 
 
Low concern High concern Low  Concern   
Delongchamps 2016 High risk Low risk Low risk Low risk 
 
Low concern Low concern Low  Concern   
Distler 2017 Low risk Low risk Low risk High risk 
 
Low concern Low concern Low Concern   
Filson 2016 Low risk Low risk Low risk Low risk 
 
Low concern Low concern Low  Concern   
Frye 2017 High risk Unclear risk Low risk Unclear risk 
 
High concern High concern Low  Concern   
Garcia Bennet 2015 Unclear risk Low risk Low risk Low risk 
 
High concern High concern Low  Concern   
Gordetsky 2017 High risk Unclear risk Low risk Unclear risk 
 
High concern High concern Low  Concern   
Günzel 2017 Low risk Low risk Low risk Unclear risk 
 
Low concern Low concern Low  Concern   
Haffner 2011 High risk High risk High risk Low risk 
 
Low concern Low concern Low  Concern   
Hansen 2016 High risk Low risk Low risk Low risk 
 
Low concern Low concern Low Concern   
Jambor 2015 High risk Low risk Low risk High risk 
 
High concern High concern Low  Concern   
Jang 2015 High risk Low risk Low risk Low risk 
 
Low concern High concern Low  Concern   
Jelidi 2017 Low risk Low risk Low risk Low risk 
 
Low concern Low concern Low Concern   
Junker 2015 Unclear risk Low risk Low risk Unclear risk 
 
Low concern Low concern Low  Concern   
Kanthabalan 2016 High risk Low risk Low risk Low risk 
 
High concern Low concern Low Concern   
Kasivisvanathan 2013 Low risk Low risk Low risk Unclear risk 
 
Low concern Low concern Low Concern   
Kasivisvanathan 20181 Low risk Low risk Low risk Low risk 
 
Low concern Low concern Low Concern   
Kaufmann 2015 High risk Low risk Low risk Low risk 
 
High concern Low concern Low  Concern   
10 
 
Low Low risk 
High High risk 
Unclear Unclear risk 
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Kroenig 2016 High risk Unclear risk Unclear risk Unclear risk 
 
Low concern High concern Low Concern   
Kuru 2013 Low risk High risk High risk Unclear risk 
 
Low concern Low concern Low Concern   
Lacetera 2016 High risk Low risk Low risk High risk 
 
High concern Low concern Low Concern   
Lai 2017 High risk Unclear risk Low risk Low risk 
 
High concern High concern Low Concern   
Lawrence 2014 Low risk Low risk High risk Unclear risk 
 
Low concern Low concern Low Concern   
Lian 2017 High risk Low risk Low risk Unclear risk 
 
Low concern Low concern Low  Concern   
Ma 2017 High risk Low risk Low risk High risk 
 
Low concern Low concern Low Concern   
Mariotti 2016 Low risk Low risk Low risk Low risk 
 
Low concern Low concern Low Concern   
Mariotti 2017 Low risk Low risk Low risk Unclear risk 
 
Low concern Low concern Low Concern   
Maxeiner 2015 Low risk Unclear risk Unclear risk Unclear risk 
 
Low concern High concern Low Concern   
Mendhiratta 2015a High risk Low risk Low risk Low risk 
 
Low concern Low concern Low Concern   
Mendhiratta 2015b High risk Low risk Low risk Low risk 
 
Low concern Low concern Low Concern   
Meng 2016 Low risk Low risk Low risk Low risk 
 
Low concern Low concern Low Concern   
Mozer 2014 High risk Low risk Low risk High risk 
 
Low concern Low concern Low Concern   
Okoro 2015 High risk High risk Low risk Unclear risk 
 
High concern High concern Low Concern   
Panebianco 20151 High risk Unclear risk High risk Unclear risk 
 
Low concern Low concern Low Concern   
Park 20111 Unclear risk High risk High risk Unclear risk 
 
Low concern High concern Low Concern   
Peltier 2015 High risk High risk High risk Unclear risk 
 
High concern High concern Low Concern   
Pepe 2016a High risk Low risk Low risk Unclear risk 
 
High concern Low concern Low Concern   
Pepe 2016b High risk Low risk Low risk Low risk 
 
Low concern Low concern Low Concern   
Pessoa 2017 High risk Low risk Low risk Low risk 
 
Low concern Low concern Low Concern   
Pokorny 2014 High risk Low risk Low risk Low risk 
 
Low concern Low concern Low Concern   
Porpiglia 20171 Low risk Low risk Low risk Low risk 
 
Low concern Low concern Low Concern   
Puech 2013 Low risk Low risk Low risk Low risk 
 
Low concern Low concern Low Concern   
Quentin 2014 High risk High risk Low risk Unclear risk 
 
Low concern Low concern Low Concern   
Reed 2017 High risk High risk Low risk Low risk 
 
High concern Low concern Low Concern   
Salami 2015 High risk Low risk Low risk Unclear risk 
 
Low concern Low concern Low Concern   
Shigemura 2012 High risk Low risk Unclear risk Low risk 
 
Low concern High concern Low Concern   
Shin 2017 Low risk High risk High risk Unclear risk 
 
Low concern High concern Low Concern   
Shoji 2015 High risk Low risk Low risk Unclear risk 
 
Low concern High concern Low Concern   
Siddiqui 2015 Low risk Low risk Low risk Low risk 
 
Low concern Low concern Low Concern   
Sonn 2014 Low risk Low risk Low risk Low risk 
 
Low concern Low concern Low Concern   
Taverna 20151 High risk High risk High risk Unclear risk 
 
Low Concern Low Concern 
Low Concern   
Tonttila 20161 High risk Low risk Low risk High risk 
 
Low concern Low concern Low Concern   
Tran 2016 High risk High risk Unclear risk Low risk 
 
Low concern Low concern Low Concern   
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1Randomised controlled trial (see additional risk of bias items below) 
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Porpiglia 2017             
Taverna 2015             
Tonttilla 2016             
 
  
12 
 
Supplementary Appendix 6 
 
Overall summary of risk of bias and applicability concerns across studies based on a 
modified Quality Assessment of Diagnostic Accuracy Studies-2 checklist. The numbers 
shown on the bars are the percentages for each judgement. 
 
  
13 
 
Supplementary Appendix 7 
 
Sensitivity analysis: forest plot of the detection ratio of MRI-targeted biopsy (MRI-TB) versus 
systematic biopsy (SB) for clinically significant cancer (CsPCa) using a Gleason 3+4 or greater 
threshold. 
 
The forest plot shows 31 study cohorts. Studies are grouped by type of comparator and 
sorted according to type of MRI-TB, coil strength and study identifier. Alphabetical suffixes 
were used to identify studies where a first author published multiple papers of non-
overlapping cohorts in the same year. DR = detection ratio. TRUS = transrectal ultrasound 
guided prostate biopsy. Template = transperineal template prostate biopsy. Cognitive = 
cognitive / visual registration; fusion = MRI/US image fusion; In-bore = carried out in the 
MRI scanner; Mixed = more than one registration method used in the study. The pooled 
summary estimate indicated that MRI-TB detected more men with clinically significant 
cancer than systematic biopsy, DR 1.09 (95% CI 1.02-1.18), p = 0.018. 
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Supplementary Appendix 8 
 
Sensitivity analysis: forest plot of the detection ratio of MRI-targeted biopsy (MRI-TB) versus 
systematic biopsy (SB) for clinically significant cancer (CsPCa) using a Gleason 4+3 or greater 
threshold. 
 
The forest plot shows 14 study cohorts. Studies are grouped by type of comparator and 
sorted according to type of MRI-TB, coil strength and study identifier. Alphabetical suffixes 
were used to identify studies where a first author published multiple papers of non-
overlapping cohorts in the same year. DR = detection ratio. TRUS = transrectal ultrasound 
guided prostate biopsy. Template = transperineal template prostate biopsy. Cognitive = 
cognitive / visual registration; fusion = MRI/US image fusion; In-bore = carried out in the 
MRI scanner; Mixed = more than one registration method used in the study. The pooled 
summary estimate indicated that MRI-TB detected more men with clinically significant 
cancer than systematic biopsy, DR 1.38 (95% CI 1.14-1.68), p = 0.001. 
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Supplementary Appendix 9 
 
Contour enhanced funnel plot for assessment of publication bias and small study effects 
based on meta-analysis of detection ratios for clinically significant cancer.  
The contour lines indicate levels of statistical significance corresponding to p <0.01, p <0.05 
and p <0.10. As indicated by the key on the plot, the regions bounded by these lines indicate 
areas of statistical significance (p < 1% and 1% < p < 5%) or non-significance (5% < p < 10% 
and p > 10%). There was indication of funnel plot asymmetry though many studies  differing 
in precision are in the regions of statistical non-significance. Therefore, publication bias or 
small study effects may be absent. A sensitivity analysis showed that exclusion of smaller 
studies did not change the conclusions of the main analysis.  Asymmetry may be due to 
other factors such as heterogeneity. 
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Supplementary Appendix 10 
 
Sensitivity analysis: forest plot of the detection ratio of MRI-targeted biopsy (MRI-TB) versus 
systematic biopsy (SB) for clinically significant cancer (CsPCa) for studies with greater than 
100 patients and 50 cancer cases diagnosed. 
 
The forest plot shows 30 study cohorts. Studies are grouped by type of MRI-TB, coil strength 
and study identifier. Alphabetical suffixes were used to identify studies where a first author 
published multiple papers of non-overlapping cohorts in the same year. DR = detection 
ratio. Cognitive = cognitive / visual registration; fusion = MRI/US image fusion; In-bore = 
carried out in the MRI scanner; Mixed = more than one registration method used in the 
study. The pooled summary estimate indicates that MRI-TB detects more clinically 
significant cancer than systematic biopsy, DR 1.19 (95% CI 1.09-1.30), p < 0.0001. 
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Supplementary Appendix 11 
 
Sensitivity analysis: forest plot of the detection ratio of MRI-targeted biopsy (MRI-TB) versus 
systematic biopsy (SB) for clinically insignificant cancer (CiPCa) using a Gleason 3+3 
definition. 
 
The forest plot shows 25 study cohorts. Studies are grouped by type of SB, type of MRI-TB, 
coil strength and study identifier. Alphabetical suffixes were used to identify studies where a 
first author published multiple papers of non-overlapping cohorts in the same year. DR = 
detection ratio. Cognitive = cognitive / visual registration; fusion = MRI/US image fusion; In-
bore = carried out in the MRI scanner; Mixed = more than one registration method used in 
the study. The pooled summary estimate indicates that MRI-TB detected fewer men with 
clinically insignificant cancer than systematic biopsy (DR 0.74 (95% CI 0.65-0.84), p < 0.0001 
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Supplementary Appendix 12 
 
Forest plot of the detection ratio of MRI-targeted biopsy (MRI-TB) versus systematic biopsy 
(SB) for any cancer (PCa).  
 
The forest plot shows 61 study cohorts. Studies are grouped by type of comparator and 
sorted according to type of MRI-TB, coil strength and study identifier. Alphabetical suffixes 
were used to identify studies where a first author published multiple papers of non-
overlapping cohorts in the same year. DR = detection ratio. TRUS = transrectal ultrasound 
guided prostate biopsy. Template = transperineal template prostate biopsy. Cognitive = 
cognitive / visual registration; fusion = MRI/US image fusion; In-bore = carried out in the 
MRI scanner; Mixed = more than one registration method used in the study. The pooled 
summary estimate indicated no difference in any cancer detection between MRI-TB and 
systematic biopsy, DR 1.02 (95% CI 0.96-1.08), p = 0.49. 
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Supplementary Appendix 13 
 
Forest plot of the proportion of cores positive for prostate cancer taken by MRI-targeted 
biopsy compared to systematic biopsy. 
 
The forest plot shows 18 study cohorts. Studies are grouped by type of comparator and 
sorted according to type of MRI-TB, coil strength and study identifier. Alphabetical suffixes 
were used to identify studies where a first author published multiple papers of non-
overlapping cohorts in the same year. RR = relative risk. TRUS = transrectal ultrasound 
guided prostate biopsy. Template = transperineal template prostate biopsy. Cognitive = 
cognitive / visual registration; fusion = MRI/US image fusion; In-bore = carried out in the 
MRI scanner; The pooled summary estimate indicated a greater proportion of cores positive 
for cancer for MRI-TB than systematic biopsy, RR 3.17 (95% CI 2.82-3.56), p = <0.0001.
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Supplementary Appendix 14 
 
Forest plot of the proportion of men with clinically significant cancer (csPCa) missed by MRI-
TB but detected by the addition of systematic biopsy. 
 
The forest plot shows 56 study cohorts. Studies are grouped by type of comparator and 
sorted according to type of MRI TB and study identifier. Alphabetical suffixes were used to 
identify studies where a first author published multiple papers of non-overlapping cohorts 
in the same year. TRUS = transrectal ultrasound guided prostate biopsy. Template = 
transperineal template prostate biopsy. Cognitive = cognitive / visual registration; fusion = 
MRI/US image fusion; In-bore = carried out in the MRI scanner; Mixed = more than one 
registration method used in the study. The pooled summary estimate indicated that the 
proportion of men with clinically significant prostate cancer missed by MRI-TB but detected 
by the addition of systematic biopsy was 0.13 [95% CI 0.10-0.16], p < 0.0001. 
 
 
